RaQualia Pharma Inc. (TYO:4579)

RaQualia Pharma Statistics

Total Valuation

RaQualia Pharma has a market cap or net worth of JPY 26.09 billion. The enterprise value is 25.60 billion.

Market Cap	26.09B
Enterprise Value	25.60B

Important Dates

The next estimated earnings date is Friday, February 13, 2026.

Earnings Date	Feb 13, 2026
Ex-Dividend Date	n/a

Share Statistics

RaQualia Pharma has 26.01 million shares outstanding. The number of shares has increased by 6.29% in one year.

Current Share Class	26.01M
Shares Outstanding	26.01M
Shares Change (YoY)	+6.29%
Shares Change (QoQ)	+2.09%
Owned by Insiders (%)	12.52%
Owned by Institutions (%)	-10.47%
Float	17.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.56
PB Ratio	4.32
P/TBV Ratio	11.30
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-35.35
EV / Sales	8.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-90.14

Financial Position

The company has a current ratio of 4.66, with a Debt / Equity ratio of 0.50.

Current Ratio	4.66
Quick Ratio	4.11
Debt / Equity	0.50
Debt / EBITDA	n/a
Debt / FCF	-10.74
Interest Coverage	-9.09

Financial Efficiency

Return on equity (ROE) is -12.41% and return on invested capital (ROIC) is -9.31%.

Return on Equity (ROE)	-12.41%
Return on Assets (ROA)	-3.44%
Return on Invested Capital (ROIC)	-9.31%
Return on Capital Employed (ROCE)	-6.23%
Weighted Average Cost of Capital (WACC)	8.12%
Revenue Per Employee	47.64M
Profits Per Employee	-11.31M
Employee Count	64
Asset Turnover	0.32
Inventory Turnover	4.31

Taxes

In the past 12 months, RaQualia Pharma has paid 167.00 million in taxes.

Income Tax	167.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +159.17% in the last 52 weeks. The beta is 0.84, so RaQualia Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	+159.17%
50-Day Moving Average	1,064.88
200-Day Moving Average	672.18
Relative Strength Index (RSI)	47.05
Average Volume (20 Days)	975,575

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RaQualia Pharma had revenue of JPY 3.05 billion and -724.12 million in losses. Loss per share was -31.50.

Revenue	3.05B
Gross Profit	2.27B
Operating Income	-530.91M
Pretax Income	-557.13M
Net Income	-724.12M
EBITDA	-51.45M
EBIT	-530.91M
Loss Per Share	-31.50

Balance Sheet

The company has 3.54 billion in cash and 3.05 billion in debt, with a net cash position of 493.79 million or 18.98 per share.

Cash & Cash Equivalents	3.54B
Total Debt	3.05B
Net Cash	493.79M
Net Cash Per Share	18.98
Equity (Book Value)	6.04B
Book Value Per Share	247.06
Working Capital	3.64B

Cash Flow

In the last 12 months, operating cash flow was -220.66 million and capital expenditures -63.34 million, giving a free cash flow of -284.00 million.

Operating Cash Flow	-220.66M
Capital Expenditures	-63.34M
Free Cash Flow	-284.00M
FCF Per Share	-10.92

Margins

Gross margin is 74.55%, with operating and profit margins of -17.41% and -23.75%.

Gross Margin	74.55%
Operating Margin	-17.41%
Pretax Margin	-18.27%
Profit Margin	-23.75%
EBITDA Margin	-1.69%
EBIT Margin	-17.41%
FCF Margin	n/a

Dividends & Yields

RaQualia Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.29%
Shareholder Yield	-6.29%
Earnings Yield	-2.78%
FCF Yield	-1.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RaQualia Pharma has an Altman Z-Score of 2.42 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.42
Piotroski F-Score	3